Brand: Cometriq
(ka'boe- zan'ti- nib)
Inhibits abnormal tyrosine kinase associated with growth and development of metastatic medullary thyroid cancer
Therapeutic outcome: Decrease in size, spread of tumor
Treatment of progressive metastatic medullary thyroid cancer
Pregnancy (D), hypersensitivity
Precautions: Breastfeeding, children, geriatric patients, cardiac/renal/hepatic/dental disease, bone marrow suppression, wound dehiscence, skin disease, MI, hypertension, proteinuria, infertility, surgery, thrombocytopenia, neutropenia, immunosuppression
BLACK BOX WARNING: Bleeding, fistula, GI bleeding/perforations
Renal dosage
Adult: PO 140 mg/day until disease progression or unacceptable toxicity
Available forms: Tabs 60, 100, 140 mg
Implementation - Take on an empty stomach; do not eat for 2 hr before and 1 hr after use; swallow whole; do not open or crush caps - Do not take with grapefruit juice - Do not take a missed dose within 12 hr of the next dose; if the next dose is in ≥ 12 hr, take the missed dose; if the next dose is in < 12 hr, skip the missed dose and take the next dose at the scheduled time - Store at room temperature
CNS: Headache, dizziness
GI: Nausea, vomiting, dyspepsia, anorexia, abdominal pain, diarrhea, GI bleeding/fistula/perforation
HEMA: Neutropenia, thrombocytopenia, bleeding
INTEG: Rash
META: Hypokalemia
MISC: Fatigue, hypothyroidism, elevated liver enzymes
MS: Arthralgia, myalgia
Distribution: Protein binding 99%
Metabolism: metabolized by CYP3 A4
Individual drugs
Increase: cabozantinib concentrations- CYP3 A4 inhibitors (ketoconazole, itraconazole, erythromycin, clarithromycin)
Increase: plasma concentrations of simvastatin, calcium channel blockers, ergots
Decrease: cabozantinib concentrations- CYP3 A4 inducers (dexamethasone, phenytoin, carBAMazepine, rifampin, PHENobarbital)
Drug/food
Increase: cabozantinib effect- grapefruit juice; avoid use while taking product
Drug/herb Cabozantinib concentration- St. John's wort
Assessment -
Proteinuria: monitor urine protein regularity; discontinue if nephritic syndrome occurs - GI bleeding/fistula/perforation: can be fatal - Wound dehiscence: discontinue product 20 days before surgery
Patient/family education - Teach patient to report adverse reactions immediately: bleeding - Explain reason for treatment, expected results - Teach that effect on male infertility is unknown
Evaluation
Positive therapeutic outcome: Decrease in size, spread of tumor
Save notes, bookmark this drug, and run formula method dosage calculations all inside the KosPharm Dashboard.
Sign in to Continue